FDA Clearance Tracker · P210029
Aptima CMV Quant Assay
Last checked: Nov 20, 2026Latest source record: May 9, 2022 (this decision)Source: openFDAMethods & limitations
Decided
May 9, 2022
Approved (reclassified)
Time to decision
287 days
Received Jul 26, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class II
The decision
- FDA number
- P210029
- Device name
- Aptima CMV Quant Assay
- Applicant
- Hologic, Inc.
- Applicant location
- San Diego, CA
- Received
- Jul 26, 2021
- Decided
- May 9, 2022
- Decision
- Approved (reclassified)
- Supplements
- 2 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3180
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval of The Aptima CMV Quant Assay - This device is approved for:The Aptima CMV Quant Assay is an in vitro nucleic acid amplification test for the quantitation of human cytomegalovirus (CMV) DNA in human EDTA plasma on the fully automated Panther system. The Aptima CMV Quant Assay is intended for use to aid in the management of solid-organ transplant patients and hematopoietic stem cell transplant patients. In patients receiving anti-CMV therapy, serial DNA measurements can be used to assess viral response to treatment. The results from Aptima CMV Quant Assay must be interpreted within the context of all relevant clinical and laboratory findings.Aptima CMV Quant Assay is not intended for use as a screening assay for the presence of CMV in blood or blood products.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code PAB. The earliest in FDA's data is P110037, decided Jul 5, 2012.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Hologic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- I-View®510(k)
K254090 · Decided Sep 2, 2026 · 257 days after receipt
Device type: Full Field Digital, System, X-Ray, Mammographic (MUE) · Radiology & Imaging
K262792 · Decided Aug 12, 2026 · 6 days after receipt
Device type: Instrument, Biopsy (KNW) · GI, Urology & Nephrology
K253634 · Decided Jun 17, 2026 · 210 days after receipt
Device type: Electrosurgical, Cutting & Coagulation & Accessories (GEI) · General & Plastic Surgery
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.